Stockscreener 앱 받기
29.65
0.07%
0.02
시간 외 거래:
29.60
-0.05
-0.17%
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
VKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized - Sahm
Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
VKTX News | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Is Viking Therapeutics Stock Going to $100? - AOL.com
Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation - Yahoo Finance
VKTX Stock Price, Quote & Chart - ChartMill
Is Viking Therapeutics Stock Going to $100? - The Motley Fool
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Taps Hubert Chen as Chief Medical Officer - Contract Pharma
Viking Therapeutics (VKTX) Appoints New Chief Medical Officer - GuruFocus
Viking Therapeutics Appoints Hubert C. Chen, M.D., as Chief Medical Officer - marketscreener.com
Viking Therapeutics appoints Hubert Chen as chief medical officer By Investing.com - Investing.com Nigeria
Viking Therapeutics Appoints Hubert Chen as Chief Medical Officer - citybiz
Viking Therapeutics appoints Hubert Chen as chief medical officer - Investing.com
Viking Therapeutics Announces Appointment Of Hubert C. Chen, M.D., As Chief Medical Officer - TradingView
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer - PR Newswire
Why 1 Wall Street analyst thinks Viking Therapeutics stock could soar 188% - MSN
VKTX eyes worst week since November as trial data looms — Wall Street still sees 200% upside - MSN
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock - AOL.com
Breaking Down VKTX: 188% Upside, Pipeline Progress and Key Risks - NAI500
Viking Therapeutics, Inc. (VKTX) falls more steeply than broader market: What investors need to know - MSN
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven (VKTX) - Seeking Alpha
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX) - The Globe and Mail
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Why (VKTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Current ratio of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Asset turnover of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Basic earnings per share (basic EPS) of Viking Therapeutics, Inc. – XETR:1VT - TradingView
ETFs Investing in Viking Therapeutics, Inc. Stocks - TradingView
Viking Therapeutics, Inc. Revenue Breakdown – XETR:1VT - TradingView
Viking Therapeutics, Inc. Cash Flow – XETR:1VT - TradingView
Viking Therapeutics, Inc. Balance Sheet – XETR:1VT - TradingView
Viking Therapeutics, Inc. Statistics – XETR:1VT - TradingView
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Obesity Drug Progress Draws Investor Attention - simplywall.st
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
InvestingPro’s overvalued call on Viking Therapeutics saves investors 41% By Investing.com - Investing.com
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider - MSN
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
1.27%
1.43%
자본화:
|
볼륨(24시간):